Search results
Results from the WOW.Com Content Network
Crizotinib [2] and cabozantinib were the first to be approved by the U.S. FDA. Crizotinib received accelerated approval in 2011 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer , while cabozantinib was approved in 2012 for the treatment of medullary thyroid cancer [ 3 ] and it has also started ...
Gastric lipase is synthesized and secreted from gastric chief cells in the stomach and is stable at pH 1,5-8, [21] but has maximum activity at pH 3-6. [20] Fat digestion begins when gastric lipase hydrolyses dietary triglycerides, by cleaving only one long-, medium- or short- acyl chain from the glyceride backbone and release free fatty acids ...
Stomach cancer, also known as gastric cancer, is a malignant tumor of the stomach. It's a cancer that develops from the lining of the stomach. [10] Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. [2]
The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity. A fundamental philosophy of medical oncology , including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent.
The Mayo Clinic diet, a program that adheres to this notion, was developed by medical professionals based on scientific research, so you can trust that this program is based on science, and not ...
There have been diets falsely attributed to Mayo Clinic for decades. [3] Many or most web sites claiming to debunk the bogus version of the diet are actually promoting it or a similar fad diet. The Mayo Clinic website appears to no longer acknowledge the existence of the false versions and prefers to promote their own researched diet. [4]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Imatinib was approved for metastatic and unresectable GIST by the U.S. FDA on February 1, 2002. The two-year survival of patients with advanced disease has risen to 75–80% following imatinib treatment. [39] If resistance to imatinib is encountered, the multiple-tyrosine-kinase inhibitor sunitinib (marketed as Sutent) can be considered.